|
KMID : 1130620240200010050
|
|
Journal of Clinical Neurology
2024 Volume.20 No. 1 p.50 ~ p.58
|
|
|
Therapeutic Outcomes and Electrophysiological Biomarkers in Anti-Myelin-Associated Glycoprotein Neuropathy: A Multicenter Cohort Study in South Korea
|
|
Min Young-Gi
Han Hee-Jo
Shin Ha-Young
Baek Jong-Gyu
Kim Jun-Soon
Park Kyung-Seok
Baek Seol-Hee
Yoo Il-Han
Huh So-Young
Kwon Young-Nam
Choi Seok-Jin
Kim Sung-Min
Hong Yoon-Ho
Sung Jung-Joon
|
|
|
Abstract
|
|
|
Background and Purpose: Unlike other immune-mediated neuropathies, anti-myelin-associated glycoprotein (MAG) neuropathy is often refractory to immunotherapy. It is necessary to compare the relative efficacies of various immunotherapies and develop objective biomarkers in order to optimize its clinical management.
Methods: This study recruited 91 patients with high anti-MAG antibody titers from 7 tertiary hospitals in South Korea. We analyzed the baseline characteristics, therapeutic outcomes, and nerve conduction study (NCS) findings of 68 patients and excluded 23 false positive cases.
Results: The rate of positive responses to treatment was highest using zanubrutinib (50%) and rituximab (36.4%), followed by corticosteroids (16.7%), immunosuppressants (9.5%), intravenous immunoglobulin (5%), and plasma exchange (0%). Disability and weakness were significantly associated with multiple NCS parameters at the time of diagnosis, especially distal compound muscle action potential (CMAP) amplitudes. Moreover, the longitudinal trajectory of the average CMAP amplitudes paralleled the clinical courses, with a 16.2 percentile decrease as an optimal cutoff for predicting a clinical exacerbation (area under the receiver operating characteristic curve=0.792).
Conclusions: Our study supports the use of NCS as an objective marker for estimating disease burden and tracking clinical changes in patients with anti-MAG neuropathy. We have described the beneficial effects of rituximab and a new drug, zanubrutinib, compared with conventional immunotherapies.
|
|
|
KEYWORD
|
|
|
anti-MAG neuropathy, immunotherapy, efficacy, biomarker, nerve conduction study
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|